Leerink Partnrs Has Optimistic Outlook of BBIO Q1 Earnings

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Stock analysts at Leerink Partnrs lifted their Q1 2025 earnings per share estimates for BridgeBio Pharma in a research report issued on Wednesday, February 26th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings per share of ($0.72) for the quarter, up from their previous estimate of ($0.73). The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($3.67) per share. Leerink Partnrs also issued estimates for BridgeBio Pharma’s Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.88) EPS, Q4 2025 earnings at ($0.84) EPS, FY2025 earnings at ($3.24) EPS, FY2026 earnings at ($1.59) EPS, FY2027 earnings at $0.61 EPS, FY2028 earnings at $3.28 EPS and FY2029 earnings at $4.88 EPS.

BridgeBio Pharma (NASDAQ:BBIO) last released its quarterly earnings results on Thursday, February 20th. The company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($1.09) by ($0.22). The company had revenue of $5.88 million during the quarter, compared to the consensus estimate of $4.04 million.

Other research analysts have also issued research reports about the company. Scotiabank lifted their price target on BridgeBio Pharma from $49.00 to $52.00 and gave the stock a “sector outperform” rating in a research report on Friday, February 21st. Evercore ISI raised their price objective on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the stock an “outperform” rating in a research note on Monday, December 23rd. Cantor Fitzgerald reissued an “overweight” rating and issued a $95.00 price objective on shares of BridgeBio Pharma in a research note on Friday, February 21st. Citigroup raised their price objective on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Finally, Bank of America raised their price objective on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, November 25th. One equities research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, BridgeBio Pharma has an average rating of “Moderate Buy” and a consensus target price of $51.67.

BridgeBio Pharma Trading Up 2.6 %

BBIO opened at $34.30 on Friday. The firm has a market cap of $6.52 billion, a P/E ratio of -12.04 and a beta of 1.07. BridgeBio Pharma has a 12 month low of $21.62 and a 12 month high of $39.47. The stock has a 50-day moving average of $32.51 and a 200 day moving average of $28.21.

Insider Activity at BridgeBio Pharma

In other BridgeBio Pharma news, CFO Brian C. Stephenson sold 8,500 shares of the company’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $33.19, for a total value of $282,115.00. Following the completion of the transaction, the chief financial officer now owns 102,464 shares in the company, valued at approximately $3,400,780.16. This represents a 7.66 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Neil Kumar sold 326,932 shares of the company’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $36.29, for a total transaction of $11,864,362.28. Following the completion of the transaction, the chief executive officer now owns 5,371,515 shares of the company’s stock, valued at approximately $194,932,279.35. This trade represents a 5.74 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 3,579,739 shares of company stock worth $125,411,901 over the last three months. Company insiders own 24.66% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Steward Partners Investment Advisory LLC raised its position in shares of BridgeBio Pharma by 85.8% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company’s stock worth $28,000 after acquiring an additional 472 shares during the period. Itau Unibanco Holding S.A. acquired a new position in shares of BridgeBio Pharma in the fourth quarter worth about $41,000. Sterling Capital Management LLC raised its position in shares of BridgeBio Pharma by 554.6% in the fourth quarter. Sterling Capital Management LLC now owns 1,787 shares of the company’s stock worth $49,000 after acquiring an additional 1,514 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of BridgeBio Pharma in the fourth quarter worth about $109,000. Finally, Advisors Asset Management Inc. raised its position in shares of BridgeBio Pharma by 56.1% in the third quarter. Advisors Asset Management Inc. now owns 4,576 shares of the company’s stock worth $117,000 after acquiring an additional 1,645 shares during the period. Institutional investors and hedge funds own 99.85% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.